Combined Treatment for Anaplastic Thyroid Carcinoma
Author Information
Author(s): Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Åkerman M, Hjelm Skog A-L, Wallin G
Primary Institution: Lund University Hospital
Hypothesis
Can a combined regimen of doxorubicin, hyperfractionated radiotherapy, and surgery improve outcomes for patients with anaplastic thyroid carcinoma?
Conclusion
The combined treatment approach improved local control and allowed some patients to survive longer than two years without recurrence.
Supporting Evidence
- 24% of patients died due to local failure.
- 60% of patients showed no signs of local recurrence.
- 9% of patients survived longer than 2 years without recurrence.
Takeaway
Doctors combined different treatments to help patients with a serious thyroid cancer, and some patients lived much longer than expected.
Methodology
Patients received a combination of hyperfractionated radiotherapy, doxorubicin, and surgery when feasible, across three different treatment protocols.
Limitations
The study included only patients with advanced anaplastic thyroid carcinoma, and the results may not be generalizable to all patients with thyroid cancer.
Participant Demographics
Patients were aged between 46 and 94 years, with a median age of 76, and a majority were female (38 females vs 17 males).
Statistical Information
P-Value
0.005
Statistical Significance
p=0.005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website